Skip to content

Mannkind MNKD Interest On Liability For Sale Of Future Royalties

Interest On Liability For Sale Of Future Royalties at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$65.7M+32.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$13.89M+6.1%
Arrowhead Research logo
Arrowhead ResearchARWR
$8.83M+60.6%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:InterestOnLiabilityForSaleOfFutureRoyalties.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's interest on liability for sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's interest on liability for sale of future royalties?
Mannkind (MNKD) reported interest on liability for sale of future royalties of $2.57M in Q1 2026.
How has Mannkind's interest on liability for sale of future royalties changed year-over-year?
Mannkind's interest on liability for sale of future royalties decreased by 28.3% year-over-year, from $3.58M to $2.57M.
What is the long-term trend for Mannkind's interest on liability for sale of future royalties?
Over 2 years (2023 to 2025), Mannkind's interest on liability for sale of future royalties has grown at a 783.8% compound annual growth rate (CAGR), from $185K to $14.45M.
What does interest on liability for sale of future royalties mean?
This represents the non-cash interest expense accrued on financial obligations tied to the monetization of future royalty streams. It reflects the cost of capital associated with upfront funding received in exchange for a portion of future product revenues.